Abstracts Archive - Page 357 of 1683 - ATC Abstracts

2020 American Transplant Congress
Impact of Donor Race on Tacrolimus Dose Requirement for Liver Transplant Recipients
N. Nesselhauf¹, S. January¹, J. Hagopian¹, K. Progar¹, A. Khan²
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Surgery, Washington University School of Medicine, St. Louis, MO
*Purpose: It is well described that there is interpatient variability in tacrolimus dose requirements among transplant recipients. CYP3A5 plays a role in this variability. Black…
2020 American Transplant Congress
Liver Transplantation as a Salvage and Uncommon Procedure for a Patient with Colorectal Liver Metastsis with Promising Results, Case Presentation and Literature Review
M. Tabbal, M. Al Qahtani
Transplant Surgery, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia
*Purpose: Colorectal cancer (CRC) is the third most common cancer worldwide. About 50% of patients with CRC will develop metastases during the course of the…
2020 American Transplant Congress
Outcomes of De Novo Belatacept-Based Immunosuppression in Recipients of Kidneys at High Risk for Delayed Graft Function in the Setting of Lymphocyte Depleting Immune Modulation
T. L. Shertel¹, M. A. Wynd¹, M. A. Pereiras¹, J. T. McKeen¹, Y. Y. Yushkov², B. R. Schleich³, S. E. Geatrakas², A. Patel², M. J. Goldstein²
¹Pharmacy, Hackensack University Medical Center, Hackensack, NJ, ²Organ Transplant, Hackensack University Medical Center, Hackensack, NJ, ³Patient Safety and Quality, Hackensack University Medical Center, Hackensack, NJ
*Purpose: Our center created an immunosuppression protocol using de novo belatacept (DNB) in the setting of lymphocyte depletion to increase the utilization of deceased donor…
2020 American Transplant Congress
Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation
T. Kitajima¹, S. Nagai¹, D. Moonka², S. Yeddula¹, O. Rizzo¹, M. Kavousi¹, R. Salgia², M. Rizzari¹, K. Collins¹, A. Yoshida¹, M. S. Abouljoud¹
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI, ²Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI
*Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…
2020 American Transplant Congress
Bad Actors within Milan Criteria Undergoing OLT- Characterizing Their Pre-Transplant Tumor Behavior and Response to Locoregional Therapy
A. Mathur, E. Baughan, A. Griesemer, M. Najjar, O. Perez, A. Qian, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Orthotopic Liver Transplantation (OLT) remains a curative option for hepatocellular carcinoma (HCC). Disparity between the supply and demand for OLT necessitates the transplant of…
2020 American Transplant Congress
Efficacy & Safety of Once Daily Tacrolimus Compared to Twice Daily Tacrolimus after Liver Transplantation
K. Bzeizi, A. Albenmousa, M. Shawkat, W. Alhamoudi, S. Alabad, R. Troisi, D. Broering
KFSHRC, Riyadh, Saudi Arabia
*Purpose: To compare the efficacy and safety of once daily prolonged release tacrolimus compared to twice daily tacrolimus in liver transplantation patients*Methods: Medline, EMBASE, CENTRAL…
2020 American Transplant Congress
Outcomes of Intra-Operative Steroid Induction in Liver Transplant Recipients
A. Poparad-Stezar, A. Jantz, T. Larson, B. Summers, N. Sulejmani
Henry Ford Hospital, Detroit, MI
*Purpose: Evidence supporting the use of antibody induction (AI) immunosuppression (IS) (antithymocyteglobulin (rATG) and basiliximab (BAS)) for acute rejection (AR) prophylaxis in liver transplant is…
2020 American Transplant Congress
Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-institutional Study Of > 3000 Patients
P. Tabrizian¹, M. Holzner², V. Agopian³, R. Busuttil³, G. Sapisochin⁴, N. Mehta⁵, F. Yao⁵, J. Roberts⁶, S. Florman¹, M. E. Schwartz¹, T. Ivanics⁷, J. Emond⁸, B. Samstein⁹, R. Brown, MD, MPH⁹, M. Najjar¹⁰, W. Chapman¹¹, M. Doyle¹¹, K. Halazun⁹
¹Transplant, Mount Sinai Medical Center, New York, NY, ²Surgery, Georgetown University Hospital, Washington DC, MD, ³Transplant, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Transplant, Univeristy of Toronto, Toronto, ON, Canada, ⁵Transplant, UCSF, San Francisco, CA, ⁶Transplantation, UCSF, San Francisco, CA, ⁷Transplant, University of Toronto, Toronto, ON, Canada, ⁸Transplant, Columbia University Medical Center, New York, NY, ⁹Transplant, Weill Cornell Medical Center, New York, NY, ¹⁰Transplant, Columbia Medical Center, New York, NY, ¹¹Transplant, Washington University School of Medicine, St Louis, MO
*Purpose: Early recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) carries a poor prognosis. We aimed to develop a risk score for early HCC…
2020 American Transplant Congress
The Impact of Initial Alpha-Fetoprotein >100 but <1,000 ng/mL and Pre-Transplant alpha-Fetoprotein Reduction on Outcomes after Liver Transplant in Patients with Hepatocellular Carcinoma
M. L. Goldman¹, K. Zhou², J. L. Dodge¹, F. Yao¹, N. Mehta¹
¹Department of Medicine, UCSF, San Francisco, CA, ²Department of Medicine, USC, Los Angeles, CA
*Purpose: Under current UNOS policy, hepatocellular carcinoma (HCC) patients with alpha-fetoprotein (AFP) >1,000 ng/mL are required to show a reduction in AFP to 100 but
2020 American Transplant Congress
Evaluation of Leukopenia and Neutropenia Incidence, Treatment, and Clinical Response in Kidney and Liver Transplant Recipients
H. Kutzler, T. Webb, R. Cecere, D. O'Sullivan, P. Sheiner
Hartford Hospital, Hartford, CT
*Purpose: The purpose is to evaluate incidence, recurrence, therapy modifications, and complications of leukopenia and neutropenia (LN) in kidney (KTR) and liver transplant (LTR) recipients.*Methods:…